Sugi Predict

Sugi Predict / Compounds / SCHEMBL1709876

SCHEMBL1709876

SCHEMBL1709876

Cc1nn(C(=O)OC(C)(C)C)c2cc([N+](=O)[O-])ccc12

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 9/20 0.47
▸ F2 P00734 5/20 0.47
▸ PLAU P00749 5/20 0.47
▸ CTRB1 P17538 5/20 0.47
▸ MAPT P10636 3/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ BRD4 O60885 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ KLKB1 P03952 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CREBBP Q92793 1/20 0.38
▸ ALOX5 P09917 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2144637 0.90 ELANE (0.47) ELANEF2PLAUCTRB1MAPT
SCHEMBL30123629 0.90 ELANE (0.47) ELANEF2PLAUCTRB1MAPT
SCHEMBL27631693 0.87 ELANE (0.56) ELANEF2PLAUCTRB1MAPT
SCHEMBL22777374 0.87 MAPT (0.44) ELANEF2PLAUCTRB1MAPT
SCHEMBL6170318 0.87 MAPT (0.44) ELANEF2PLAUCTRB1MAPT
SCHEMBL3964153 0.87 MAPT (0.44) ELANEF2PLAUCTRB1MAPT
SCHEMBL27585778 0.85 ELANE (0.42) ELANEF2PLAUCTRB1MAPT
SCHEMBL2922296 0.84 ELANE (0.41) ELANEF2PLAUCTRB1MAPT
SCHEMBL30833809 0.83 ELANE (0.41) ELANEF2PLAUCTRB1MAPT
SCHEMBL6375106 0.83 L3MBTL1 (0.52) ELANEF2PLAUCTRB1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606544-B2 JAK1 selective kinase inhibitor DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2026-04-21 — — US disclosed
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 — — US disclosed
EP-3956322-B1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2025-05-14 — — EP disclosed
CN-113727972-B Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof 韩国科学技术研究院 2024-12-27 — — CN disclosed
CN-113710664-B JAK1 selective kinase inhibitors 迪哲(江苏)医药股份有限公司 2024-01-26 — — CN disclosed
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-15 — — US disclosed
US-20220220096-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2022-07-14 — — US disclosed
EP-3956322-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2022-02-23 — — EP disclosed
CN-113727972-A Novel hydrazone derivatives in which terminal amino group is substituted with aryl or heteroaryl group, and use thereof 韩国科学技术研究院 2021-11-30 — — CN disclosed
CN-113710664-A JAK1 selective kinase inhibitors 迪哲(江苏)医药股份有限公司 2021-11-26 — — CN disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 — — US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 — — US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 — — EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 — — WO disclosed
WO-2007023114-A1 P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 — — WO disclosed
EP-1019045-B1 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2005-06-08 — — EP disclosed
US-20030078431-A1 Antithrombotic agents BEIGHT DOUGLAS WADE (US) 2003-04-24 — — US disclosed
US-6500851-B2 ANTICOAGULANT IN MAMMLS ELI LILLY AND COMPANY 2002-12-31 — — US disclosed
US-20020173518-A1 Antithrombotic agents BEIGHT DOUGLAS WADE (US) 2002-11-21 — — US disclosed
US-6372759-B1 BLOOD COAGULATION FACTOR XA FOR MAMMALS ELI LILLY AND COMPANY 2002-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220096-A1 JAK1 SELECTIVE KINASE INHIBITOR JAK1, JAK2, JAK3 ELANE 1830/4885F2 2321/4885PLAU 2907/4885
US-20020173518-A1 Antithrombotic agents SERPINC1, TFPI, F11 ELANE 153/4885F2 5/4885PLAU 43/4885
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K ELANE 4175/4885F2 3621/4885PLAU 3768/4885
US-12606544-B2 JAK1 selective kinase inhibitor JAK1, JAK2, JAK3 ELANE 3081/4885F2 3994/4885PLAU 4431/4885
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof ABL1, TH, CYP3A43 ELANE 1888/4885F2 1661/4885PLAU 4707/4885
US-20030078431-A1 Antithrombotic agents SERPINC1, TFPI, F11 ELANE 153/4885F2 5/4885PLAU 43/4885
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF AANAT, NAT1, HNMT ELANE 1906/4885F2 4005/4885PLAU 4042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.